These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Prostate cancer treated with androgen deprivation therapy has consequences for bone. Adler RA Endocrine; 2014 Apr; 45(3):339-40. PubMed ID: 24366636 [No Abstract] [Full Text] [Related]
7. Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? Turco F; Tucci M; Buttigliero C Minerva Urol Nephrol; 2021 Dec; 73(6):870-872. PubMed ID: 35144376 [No Abstract] [Full Text] [Related]
8. Intensification of Androgen Deprivation Therapy in High-Risk, Nonmetastatic Prostate Cancer: Lessons From STAMPEDE. Gong J; Posadas EM JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35877083 [No Abstract] [Full Text] [Related]
9. Prostate cancer: Bone density testing--essential or extraneous? Yu EY Nat Rev Urol; 2013 Jan; 10(1):11-2. PubMed ID: 23229500 [No Abstract] [Full Text] [Related]
10. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study. Ng HS; Koczwara B; Roder D; Vitry A Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):403-410. PubMed ID: 29720722 [TBL] [Abstract][Full Text] [Related]
13. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Owen PJ; Daly RM; Livingston PM; Fraser SF Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):137-145. PubMed ID: 28117386 [TBL] [Abstract][Full Text] [Related]
14. Bone health management in prostate cancer patients receiving androgen deprivation therapy. Dhanapal V; Reeves DJ J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761 [TBL] [Abstract][Full Text] [Related]
15. Hormone Treatment of Prostate Cancer:: Evidence for Usage and Safety. Labban M; Alkassis M; Alkhatib K; Briggs L; Cole AP; Kibel AS; Trinh QD Urol Clin North Am; 2022 May; 49(2):309-321. PubMed ID: 35428436 [TBL] [Abstract][Full Text] [Related]
16. Unsafe testosterone-based dosing regimen of androgen deprivation therapy in patients with locally advanced or metastatic prostate cancer: a prematurely ended randomized controlled trial (MIDAS-trial). Mulder MB; Birnie E; van Dijck-van Boetzelaer C; van de Geijn GJ; Boevé E; Westerman EM; Hamberg P Acta Oncol; 2021 Apr; 60(4):539-543. PubMed ID: 33356721 [No Abstract] [Full Text] [Related]
17. Managing complications of androgen deprivation therapy for prostate cancer. Holzbeierlein JM Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456 [TBL] [Abstract][Full Text] [Related]
18. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618 [TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation in prostate cancer and the long-term risk of fracture. Ojeda S; Lloret M; Naranjo A; Déniz F; Chesa N; Domínguez C; Lara PC Actas Urol Esp; 2017 Oct; 41(8):491-496. PubMed ID: 28259363 [TBL] [Abstract][Full Text] [Related]
20. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]